Etanercept( —— )

Catalog No. M34947 CAS No. 185243-69-0

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Get Quotation Bulk Inquiry Add to Cart

Product Name

Etanercept
Note

Research use only, not for human use.
Brief Description

Etanercept is a fusion protein consisting of the soluble portion of the p75-tumor necrosis factor receptor (TNFR) and the Fc fragment of human IgG1 and is commonly used to treat patients with rheumatoid arthritis.
Description

Etanercept, a dimeric fusion protein that binds TNF, acts as a TNF inhibitor. Etanercept competitively inhibits the binding of both TNF-α and TNF-β to cell surface TNF receptors, rendering TNF biologically inactive. Etanercept shows efficacy against rheumatoid arthritis, juvenile idiopathic arthritis, and plaque psoriasis.
In Vitro

——
In Vivo

Etanercept (10 mg/kg; s.c.; every 3 days for 3 weeks) significantly decreases the mean arthritis scores and radiological score.Animal Model:Six-week-old male Lewis rats (adjuvant-induced arthritis (AIA) model) Dosage:10 mg/kg Administration:S.c.; every 3 days for 3 weeks Result:Significantly decreased the mean arthritis scores; Significant decreased in radiological score at the end of the treatment period.
Synonyms

——
Pathway

Apoptosis
Target

TNF
Recptor

TNF
Research Area

——
Indication

——

1. Goffe B, et al. Etanercept: An overview. J Am Acad Dermatol. 2003;49(2 Suppl):S105-S111.?

Calculator

molnova catalog